Skip to main content

Table 1 Patient demographics and baseline characteristics (N = 93)

From: Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study

Characteristic

Value$

Age, years

40.0 ± 12.4

Sex, no. (%)

 Male

50 (53.8)

 Female

43 (46.2)

BM blasts, %

0.4 ± 0.3

HB, g/dL

91.0 ± 25.3

WBC, × 109/L

9.2 ± 15.9

PLT, × 109/L

69.5 ± 66.4

ECOG PS, no. (%)

 0

34 (36.6)

 1

42 (45.2)

 2

16 (17.2)

 3

1 (1.1)

FAB classification, no. (%)

 M0

2 (2.2)

 M1

3 (3.2)

 M2

49 (52.7)

 M4

14 (15.1)

 M5

24 (25.8)

 M6

1 (1.1)

Diagnosis, no. (%)

 Refractory

37 (39.8)

 Early relapse

38 (40.9)

 Late relapse

18 (19.4)

Antecedent hematologic disorders, no. (%)

 Myelodysplastic syndromes

3 (3.2)

 Aplastic anemia

1 (1.1)

Prior therapies, no. (%)

 0–5

52 (55.9)

 6–10

28 (30.1)

 ≥ 11

13 (14.0)

Prior therapy, no. (%)

 Prior epigenetic agents

17 (18.3)

 Prior allogeneic stem cell transplant

2 (2.2)

Karyotype, no. (%)

 Normal karyotype

54 (58.1)

 Complex karyotype#

9 (9.7)

 T (8; 21)

13 (14.0)

Mutation counts, no. (%)*

 0

12 (13.6)

 1

20 (22.7)

 2

22 (25.0)

 3

19 (21.6)

 4

12 (13.6)

 5

3 (3.4)

  1. Abbreviations: BM bone marrow, HB hemoglobin, WBC white blood cell count, PLT platelets, ECOG PS Eastern Cooperative Oncology Group performance score, FAB French-American-British, CEBPA-dm CEPBA double mutation
  2. $Descriptive statistics were presented as the mean ± standard deviation (mean ± SD) for continuous data and as numbers and percentages for dichotomous/categorical data
  3. *Measured in 88 patients who underwent gene mutation detection
  4. #Complex karyotype was defined as ≥ 3 clonal chromosomal abnormalities